Pomecin
| Source | SynBio Database www.ulprospector.com/en/na/PersonalCare/Detail/2850… |
|---|---|
| Organization | Evolva |
| Market status | Early Stage Concept |
| Industry | Food & Agriculture |
| Value chain stage | Input |
| Production process | Closed Production |
| Business models | B2B |
| Product categories | Plant |
| Biotech components | Plant |
| Organization type(s) | Public Company |
| Funding types | Shareholder Investment |
| Known funding amount | 86,000,000 CHF |
| Country of production | Switzerland |
| Trading symbol | EVE |
| Trading exchange | SWX |
| Notes | Evolva no longer exploring Pomecin production. See: http://www.evolva.com/press-release/evolva-acquires-resveratrol-programme-from-fluxome/. No information available on product pipeline. |
| Additional link #1 | www.six-swiss-exchange.com/issuers/services/tensid_news_e… |